Bridging Capital to the Future of Health: Why We Backed Cloudbreak Pharma’s HKEX IPO
At Reynold Lemkins Group, our mission goes beyond capital deployment — it’s about empowering the companies that are actively redefining their fields. We believe that truly transformative growth happens at the intersection of visionary innovation and strategic, patient capital.
That’s why we’re incredibly proud to announce our significant cornerstone investment in the initial public offering (IPO) of Cloudbreak Pharma (02592.HK) on the Hong Kong Stock Exchange (HKEX). This investment is a powerful testament to our belief in visionary biotech companies that are addressing global challenges with life-changing science.
Cloudbreak Pharma is a pioneer in clinical-stage ophthalmic biotechnology. Their HKD 612 million growth-focused IPO will fuel critical R&D and commercialization efforts for innovative therapies like CBT-001, a potential world-first non-surgical treatment for pterygium that is already in Phase 3 U.S./China trials. As cornerstone investors, our commitment of USD 22.8 million, alongside a total of approximately USD 45.6 million in cornerstone investment, underscores our confidence in their path forward.
Our role as a cornerstone investor in this HKEX listing is a core part of our mission to serve as a crucial cross-border capital partner. We leverage our deep expertise in navigating complex international markets to act as a bridge, connecting promising innovation from Asia with global investment. This strategic focus is a consistent thread in our work, including our prior participation in the successful IPO of VISEN Pharmaceuticals (HKEX: 02561), which similarly attracted strong institutional demand and aligned with our commitment to scalable businesses.
As our President and Chief Investment Officer, Kris Haoran Liu, said, “Cloudbreak Pharma epitomizes Reynold Lemkins Group’s core philosophy: empowering companies that are truly transforming their fields. We’re proud to back a biotech pioneer bringing life-changing science to global health. This investment perfectly aligns with our drive to bridge cross-border capital with transformative growth, creating lasting value.”
The success of Cloudbreak Pharma’s IPO is just the beginning of a new chapter. We are dedicated to providing the strategic capital these ventures need to scale, innovate, and deliver on their promise to the world.
To learn more about our investment philosophy and the ventures we support, visit our website or connect with us on LinkedIn.
